As rumors about Apple's glucose tracker intensify, a look at scientific and technological challenges to non-invasive blood sugar monitoring
Rachel Becker / The Verge :
Context & Ripple Effects
The Verge's explainer lands two weeks after CNBC reported Apple had hired a small team of biomedical engineers who had been working on non-invasive glucose sensors for five-plus years, followed by word of feasibility trials at clinical sites across the Bay Area. The piece exists to cool those rumors down: the reporting describes an active program, while the science describes why no one has shipped this yet.
What makes the story durable is what came after it — Bloomberg's later look inside Apple's Exploratory Design Group, still listing a glucose monitor among its projects, and 2024 reporting that Apple tested a prediabetes app as part of the same push. The arc shows Apple treating blood sugar as a long-horizon platform bet, not a feature for the next product cycle.
First-order effects
- Apple's biomedical team faces the immediate burden of proving at its Bay Area clinical trial sites that optical sensing can match the accuracy of needle-based readings — the gap The Verge identifies between the rumor and the physics.
- For people with diabetes watching the rumors, the practical effect right now is expectation-setting: coverage frames glucose tracking on a watch as scientifically unresolved rather than imminent, tempering what the market assumes Apple can announce.
Second-order effects
- If Apple ever validates the approach, rival wearable makers would face consumer expectations that their devices should sense blood sugar too, forcing them into similar multi-year biomedical programs or partnerships they don't yet have.
- A consumer company entering glucose measurement pulls adjacent software into scope — exactly what Apple's tested prediabetes app suggests, where the sensor's value depends on food-tracking and lifestyle tooling built around it.
Third-order effects
- The seven-year span from the 2017 hiring reports through the Exploratory Design Group coverage points to a structural shift: health sensing moving from accessory apps to core silicon-and-sensor work that only companies with Apple-scale resources can sustain.
- If non-invasive glucose ever clears its accuracy bar, the boundary between wellness gadgets and medical devices blurs, putting consumer wearables under the kind of clinical validation and regulatory scrutiny that today applies only to prescribed monitors.
The trend: Consumer wearables are inching toward medical-grade sensing, and Apple's multi-year, still-unshipped glucose effort shows how wide the gap remains between a rumored capability and a validated product.